This work confirms the translational potential of a PARP - 1
PET imaging agent and supports future clinical trials to test PARP - 1 expression as a method to stratify patients for PARP inhibitor therapy.
Not exact matches
For this research, a total of 28 subjects were imaged with a variety of
imaging modalities, including standard
imaging with computed tomography, magnetic resonance
imaging and molecular bone scan (SI);
PET with a common radiotracer called fluorodeoxyglucose (FDG -
PET); and
PET with computed tomography and the
agent Zr - 89 IAB2M (IAB2M
PET / CT) assessed in escalated doses.
In the study, the
imaging agent — Ga - 68 prostate - specific membrane antigen (Ga - 68 PSMA)-- used with positron emission tomography and computed tomography (
PET / CT), changed management in 44 % more cases than another widely used
agent.
For this study, 10 subjects with Alzheimer's underwent
PET following the injection of three radiotracers: fluorine - 18 fluorodeoxyglucose (F - 18 FDG), which images regional metabolic activity; carbon - 11 Pittsburgh compound B (C - 11 PiB), which has an affinity for amyloid plaques; and F - 18 AV - 1451, an emerging
imaging agent that binds to tau in the brain.
Another project enabled the first FDA - approved
imaging agent that could be used in
PET scans of Alzheimer's patients who were still alive.
18F - AV - 1451 is a brain
imaging agent used in
PET (Positron Emission Tomography) Scans.
This includes - but is not limited to -
PET / CT, contrast
agents for MRI, fMRI, CT and U / S, plus all optical
imaging agents.